San Francisco, CA, United States of America

Todd C Zankel

This inventor holds 16 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Neurological Treatments. Top assignees: Horizon Orphan LLC, Raptor Pharmaceuticals Inc., Raptor Pharmaceutical Corp. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Todd C Zankel. Retrieved from https://idiyas.com/inventor/todd-c-zankel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 10)

% Patents Active = 18.8

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 5)

Average Co-Inventor Count = 2.3

ph-index = 7

Forward Citations = 108(Granted Patents)

Location History:

Novato, CA (US) (2013 - 2021)
San Francisco, CA (US) (2009 - 2022)

Company Filing History:

Raptor Pharmaceuticals Inc.

patents

3 out of 6

Raptor Pharmaceutical Corp

patents

4. 2 out of 2

Bioasis Advanced Technologies Inc.

patents

5. 1 out of 1

Mercaptor Discoveries, Inc.

patent

Years Active: 2009-2024

Loading Chart...

Areas of Expertise:

Thiol Compounds

Neurological Disease

Enzyme Delivery

Fucosidase Inhibitors

Receptor-Associated Protein

Therapeutic Compounds

Lysosomal Enzymes

Brain Delivery

Active Agents

Liver Disorders

CR-Containing Proteins

RAP Conjugates

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12128014 - Use of thiol compounds to treat neurological disease (2024-10-29),

2. 11505550 - ADO-resistant cysteamine analogs and uses thereof (2022-11-22),

3. 10906904 - ADO-resistant cysteamine analogs and uses thereof (2021-02-02),

4. 10716862 - Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes (2020-07-21),

5. 10308607 - Fucosidase inhibitors (2019-06-04),

6. 9951013 - Fucosidase inhibitors (2018-04-24),

7. 9879064 - Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof (2018-01-30),

8. 9062126 - Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof (2015-06-23),

9. 8877714 - Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof (2014-11-04),

10. 8795627 - Treatment of liver disorders by administration of RAP conjugates (2014-08-05),

11. 8609103 - Megalin-based delivery of therapeutic compounds to the brain and other tissues (2013-12-17),

12. 8546319 - Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes (2013-10-01),

13. 8440629 - Cyclic receptor-associated protein (RAP) peptides (2013-05-14),

14. 7829537 - Receptor associated protein (RAP) conjugates (2010-11-09),

15. 7569544 - Methods of increasing delivery of active agents to brain comprising administering receptor associated protein (RAP) fragments conjugated to active agents (2009-08-04),

Title: Unveiling the Inventive Mind of Todd C Zankel

Introduction:

Todd C Zankel, a prolific inventor hailing from San Francisco, CA, has left an indelible mark on the world of innovation with his groundbreaking work. With an impressive 15 patents to his name, Todd's relentless pursuit of advancements in medical treatments has garnered widespread acclaim.

Latest Patents:

Among his latest patents is the revolutionary "ADO-resistant cysteamine analogs and uses thereof" - a method aimed at treating diseases where cysteamine is essential. This innovative approach showcases Todd's dedication to addressing crucial medical needs through inventive solutions.

Career Highlights:

Throughout his career, Todd C Zankel has contributed significantly to renowned companies such as Raptor Pharmaceuticals Inc. and Horizon Orphan LLC. His expertise and ingenuity have played a pivotal role in driving advancements in the pharmaceutical industry, benefiting countless individuals worldwide.

Collaborations:

In his quest for innovation, Todd has collaborated with esteemed professionals in the field, including Christopher M Starr and Sara Louise Isbell. Together, they have worked tirelessly to push the boundaries of what is possible in the realm of medical treatments, paving the way for a brighter, healthier future.

Conclusion:

In conclusion, Todd C Zankel's unwavering commitment to innovation and his remarkable portfolio of patents are a testament to his exceptional talents as an inventor. His contributions have not only enriched the field of medicine but have also inspired a new generation of inventors to push the limits of what is achievable. Todd's impact will continue to be felt for years to come, shaping the landscape of innovation for the better.

Profile summary based on public USPTO records.